Invega Sustenna is a medication used in the treatment of schizophrenia. It belongs to the class of drugs called atypical antipsychotics, and is known for its effectiveness in managing the symptoms of schizophrenia. However, it is important to have a thorough understanding of Invega Sustenna Prescribing Information before prescribing it to patients.
Invega Sustenna Prescribing Information contains the dosage and administration information, indications and usage, contraindications, warnings and precautions, adverse reactions, drug interactions, and usage in specific populations.
Dosage and Administration:
Invega Sustenna is administered intramuscularly in the deltoid or gluteal muscle. The recommended dose is 39 mg every four weeks. A starting dose of 78 mg is administered on day one and another dose of 78 mg is administered a week later.
Indications and Usage:
Invega Sustenna is indicated for the treatment of schizophrenia in adults. It is also used for the maintenance treatment of schizophrenia.
Contraindications:
Invega Sustenna should not be prescribed to patients who have a known hypersensitivity to paliperidone or any of the inactive ingredients in Invega Sustenna. It should not be used in patients with a history of neuroleptic malignant syndrome (NMS).
Warnings and Precautions:
Invega Sustenna should be used with caution in patients with a history of cardiovascular or cerebrovascular disease, diabetes mellitus, seizures, or with conditions that increase the risk of QT prolongation. It may also cause metabolic changes that can increase cardiovascular and cerebrovascular risk in patients.
Adverse Reactions:
The most common adverse reactions associated with Invega Sustenna are injection site reactions, weight gain, extrapyramidal symptoms, restlessness, and sleepiness. It may also cause changes in the metabolic profile of patients, leading to diabetes mellitus, hyperlipidemia, and weight gain. Other adverse reactions may include tremors, akathisia, dystonia, tardive dyskinesia, and malignant syndrome.
Drug Interactions:
Invega Sustenna may interact with other medications, including CYP3A4 inhibitors, and drugs that prolong the QT interval. It should not be used with other antipsychotic medications.
Usage in Specific Populations:
Invega Sustenna should be used with caution in patients with hepatic impairment, renal impairment, and in geriatric patients. It is not recommended for use in pregnant or breastfeeding women.
In conclusion, Invega Sustenna Prescribing Information provides crucial information for healthcare providers when prescribing this medication to their patients. The information contained in the prescribing information helps to ensure safe and effective use of Invega Sustenna in patients with schizophrenia. It is important to carefully review the prescribing information before prescribing Invega Sustenna to any patient.
